Serotonin type 6 receptor antagonists: recent progress in sustainable synthesis methods and novel therapeutic applications
The area of research on neurodegenerative and psychiatric diseases is one of the main research priorities of the European Union programs. As a multidisciplinary exchange platform in the fields of medical chemistry, structural and molecular biology and pharmacology, the symposium will be an opportunity to discuss the directions for the development of new therapeutic approaches in the treatment of central nervous system diseases. In order to develop more comprehensive strategies for searching for compounds with biological activity, the subject of the meeting will focus on increasing the synergy between the activities of distributed research teams from various fields.
The aim of the two-day symposium is to discuss the achievements and challenges related to the development of drugs for the treatment of civilization diseases, with particular emphasis on issues related to I) methods of synthesizing biologically active compounds, i.e. flow chemistry and mechanochemistry, II) new indications for original molecules in neurodegenerative diseases, psychiatric disease and neuropathic pain; and III) analysis of potential biological targets for the development of new drugs for the treatment of multifactorial CNS diseases. The above goals will be discussed in the context of the sustainable development of society.
The symposium is co-organized by the Scientific Center of the Polish Academy of Sciences in Paris, the Jagiellonian University-Collegium Medicum, the University of Montpellier, The Institute Max Mousseron of Biomecules (IBMM) and the Institute of Functional Genomics of Montpellier (IGF).